Affiliation:
1. Peking Union Medical college Hospital, Chinese Academy of Medical Science & Peking Union Medical College
Abstract
Abstract
Background
We investigated the real-world efficacy of adjuvant therapy for stage I lung adenocarcinoma patients with pathological high-risk factors.
Methods
Study participants were enrolled from November 1, 2016 and April 30, 2022. Clinical bias was balanced by propensity score matching. Disease-free survival (DFS) outcomes were compared by Kaplan–Meier analysis. The Cox proportional hazards regression was used to identify survival-associated factors. p ≤ 0.05 was the threshold for statistical significance.
Results
A total of 658 patients, among whom 195 (29.6%) underwent adjuvant therapy, were enrolled in this study. One hundred and sixty-seven of the patients who underwent adjuvant therapy were well matched with non-treatment patients. Prognostic outcomes of the treatment group were significantly better than those of the non-treatment group, as revealed by Kaplan-Meier analysis before and after PSM. Differences in prevention of recurrence or metastasis between the targeted therapy and chemotherapy groups were insignificant. Patients with multiple risk factors, stage IB and who were non-smokers were more likely to benefit from adjuvant treatment. Adjuvant therapy was found to be positive prognostic factors.
Conclusions
Adjuvant therapy significantly improved the DFS for stage I lung adenocarcinoma patients with high-risk factors. Larger prospective clinical trials should be performed to verify our findings.
Publisher
Research Square Platform LLC